We target to acquire exclusive PRC distribution rights of the following pharmaceutical products from Japanese and U.S. pharmaceutical companies within the first quarter of 2020: . Treatment of a rare type of hematological tumor disease (an orphan disease in Japan and the United States): The right to commercialize this pharmaceutical product has been approved in Japan and the United States. According to our internal market analysis, there are currently over 5,000 patients with such disease in China and no approved therapeutic drug treatment in the PRC market. The market size upon successful commercialization of the drug in China is estimated at approximately RMB50 million. BUSINESS – 162 –
. Treatment of an orphan disease of the nervous system: This pharmaceutical product is an oral agent that has been listed on the international treatment guideline of the disease. The right to commercialize this product has been approved in the United States, with global annual sales of over US$3 billion in 2018. According to our internal market analysis, there are currently over 100,000 patients with such disease in China and there are only two approved therapeutic drugs in the PRC market. We estimate the first drug held a market share of over 90% by sales in 2018 and has been included in the NRDL since 2017, while the second drug entered the market in 2018. We believe our target pharmaceutical product will be a competitive addition in the PRC market as we estimate its global sales are greater than that of the other two drugs.